• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

MK-4827 (R-enantiomer)

(CAS: 1038915-58-0)

Suppliers of MK-4827 (R-enantiomer)

Company Name Email Tel Country
CHEMSCENE, LLC [email protected] 732-484-9848 USA

Fax: 888-484-5008Purity: Brand:

Price and Availability: USD220/5mg () USD380/10mg ()

MedChemexpress Co., Ltd. [email protected] 609-228-6898 USA

Fax: 609-228-5909Purity: Brand:

Price and Availability: USD220/5mg () USD380/10mg ()
Quality Control & MSDS Files: MSDS CoA HNMR LCMS MSDS CoA HNMR LCMS

Shanghai Haoyuan Chemexpress Co., Ltd. [email protected] +86 (21) 5187-0955 / +86 (21) 5895-5995 China

Fax: +86 (21) 5895-5996Purity: Brand:

Price and Availability: USD220/5mg () USD380/10mg ()

Inquiry Online

Salutation: *Country:
*Customer: *Company Name:
*Email: *Request quantity:
Remarks:
 

Notice: Your contact information will be sent to selected suppliers.

* Required Fields.

Background Information of MK-4827 (R-enantiomer)

MK-4827 R-enantiomer is the R form of MK-4827(Niraparib), which is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM; with great activity in cancer cells with mutant BRCA-1 and BRCA-2; >330-fold selective against PARP3, V-PARP and Tank1. IC50 value: 3.8 nM/2.1 nM( PARP1/2) [1] Target: PARP1/2 in vitro: MK-4827 displays excellent PARP 1 and 2 inhibition with IC(50) = 3.8 and 2.1 nM, respectively, and in a whole cell assay, it inhibits PARP activity with EC(50) = 4 nM and inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC(50) in the 10-100 nM range [1].

Solubility of MK-4827 (R-enantiomer)

Solubility Sources

Storage Condition of MK-4827 (R-enantiomer)

Storage Condition Sources

MSDS Information

MSDS Sources
MedChemexpress Co., Ltd.
MedChemexpress Co., Ltd.

Quality Control and Spectral Data

QC Reports Sources
[CoA] [HNMR] [LCMS] MedChemexpress Co., Ltd.

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
MK-4827 (R-enantiomer) Tesaro, Inc.; European Organisation for Research and Treatment of Cancer - EORTC; Breast International Group; Myriad Genetic Laboratories, Inc.; US Oncology Research; Sarah Cannon; Facing Our Risk of Cancer Empowered (FORCE) Carcinoma of Breast; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; BRCA1 Gene Mutation; BRCA2 Gene Mutation 2013/10/01 2015/10/01 Phase 3 Clinical
MK-4827 (R-enantiomer) Merck Sharp & Dohme Corp. Lymphoma; Mantle-Cell 2010/12/01 2013/8/01 Phase 2 Clinical
MK-4827 (R-enantiomer) - No Development Reported

Chemical Information

M.Wt Formula CAS No. Synonyms
320.39 C19H20N4O 1038915-58-0 Niraparib R-enantiomer; MK 4827 R-enantiomer; MK4827 R-enantiomer; (R)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

Structure Information of MK-4827 (R-enantiomer)

Smiles O=C(C1=CC=CC2=CN(C3=CC=C([[email protected]@H]4CNCCC4)C=C3)N=C12)N
InChI InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m0/s1

Related Products

Other Form Products of MK-4827 (R-enantiomer)

Name CAS Formula Suppliers
2-(4-(Piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide 1038915-75-1 C19H20N4O 7
MK-4827 (tosylate) 1038915-73-9 C26H28N4O4S 13
MK-4827 (hydrochloride) 1038915-64-8 C19H21ClN4O 9
MK-4827 1038915-60-4 C19H20N4O 14

Recommended Products in Same Target

Name CAS Formula Suppliers
2-(4-(Piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide 1038915-75-1 C19H20N4O 7
MK-4827 (tosylate) 1038915-73-9 C26H28N4O4S 13
Nicotinamide 98-92-0 C6H6N2O 27
NVP-TNKS656 1419949-20-4 C27H34N4O5 12
JW 55 664993-53-7 C25H26N2O5 21
PJ34 344458-19-1 C17H17N3O2 12
PJ34 (hydrochloride) 344458-15-7 C17H18ClN3O2 24
AZD-2461 1174043-16-3 C22H22FN3O3 17
BMN-673 (8R,9S) 1207456-00-5 C19H14F2N6O 12
BMN-673 1207456-01-6 C19H14F2N6O 16
UPF 1069 1048371-03-4 C17H13NO3 20
MK-4827 (hydrochloride) 1038915-64-8 C19H21ClN4O 9
MK-4827 1038915-60-4 C19H20N4O 14
Rucaparib 283173-50-2 C19H18FN3O 13
Rucaparib (phosphate) 459868-92-9 C19H21FN3O5P 18
A-966492 934162-61-5 C18H17FN4O 14
XAV-939 284028-89-3 C14H11F3N2OS 16
AG14361 328543-09-5 C19H20N4O 15
INO-1001 3544-24-9 C7H8N2O 17
BSI-201 160003-66-7 C7H5IN2O3 20

Recommended Products in the Same Indication

Name CAS Formula Suppliers

Chemical and Physical Properties

Appearance: Melting point:
Boiling point: Flash Point:
Water Solubility: Solubility:
Density: Merck:
BRN: Refractive Index:
Vapour: EINECS:
Optical Rotation: alpha:

Tags: buy MK-4827 (R-enantiomer) | MK-4827 (R-enantiomer) IC50 | MK-4827 (R-enantiomer) price | MK-4827 (R-enantiomer) cost | MK-4827 (R-enantiomer) solubility | MK-4827 (R-enantiomer) purchase | MK-4827 (R-enantiomer) manufacturer | MK-4827 (R-enantiomer) research buy | MK-4827 (R-enantiomer) order | MK-4827 (R-enantiomer) MSDS | MK-4827 (R-enantiomer) chemical structure | MK-4827 (R-enantiomer) Storage condition | MK-4827 (R-enantiomer) molecular weight | MK-4827 (R-enantiomer) mw | MK-4827 (R-enantiomer) datasheet | MK-4827 (R-enantiomer) supplier | MK-4827 (R-enantiomer) cell line | MK-4827 (R-enantiomer) NMR | MK-4827 (R-enantiomer) MS | MK-4827 (R-enantiomer) IR | MK-4827 (R-enantiomer) solubility | MK-4827 (R-enantiomer) Safe information | MK-4827 (R-enantiomer) Qc and Spectral Information | MK-4827 (R-enantiomer) Clinical Information | MK-4827 (R-enantiomer) Clinical Trial | MK-4827 (R-enantiomer) Route of Synthesis | MK-4827 (R-enantiomer) storage condition | MK-4827 (R-enantiomer) diseases and conditions | MK-4827 (R-enantiomer) flash point | MK-4827 (R-enantiomer) boiling point | MK-4827 (R-enantiomer) melting point | MK-4827 (R-enantiomer) storage condition | MK-4827 (R-enantiomer) brand